FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $341,845 | -34.8% | 71,679 | -22.1% | 0.00% | 0.0% |
| Q1 2023 | $524,520 | -22.2% | 92,021 | +37.7% | 0.00% | -50.0% |
| Q4 2022 | $674,244 | -48.3% | 66,823 | +14.8% | 0.00% | -50.0% |
| Q3 2022 | $1,304,000 | -5.2% | 58,185 | +4.8% | 0.00% | +33.3% |
| Q2 2022 | $1,376,000 | -31.1% | 55,526 | +7.9% | 0.00% | +50.0% |
| Q1 2022 | $1,996,000 | +59.9% | 51,482 | +141.4% | 0.00% | -33.3% |
| Q4 2021 | $1,248,000 | +19.4% | 21,330 | +20.9% | 0.00% | 0.0% |
| Q3 2021 | $1,045,000 | -14.9% | 17,642 | +24.7% | 0.00% | 0.0% |
| Q2 2021 | $1,228,000 | +22.8% | 14,144 | +16.6% | 0.00% | 0.0% |
| Q1 2021 | $1,000,000 | – | 12,133 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |